Detected ·
AtaiBeckley
$3.8B—
Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion — the biggest deal in psychedelic medicine to date. The deal centers on BPL-003, a 5-MeO-DMT-based drug that showed strong Phase 2 results in treatment-resistant depression.
- Website
- www.ataibeckley.com
- linkedin.com/company/ataibeckley
- Amount
- $3 800 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-18 04:06:36 UTC
- Signal ID
- f518b0bb-20d6-4283-88c3-54fb8caed8ba
As the API returns it
{
"id": "f518b0bb-20d6-4283-88c3-54fb8caed8ba",
"created_at": "2026-07-18T04:06:36.602176Z",
"company_name": "AtaiBeckley",
"company_website_url": "www.ataibeckley.com",
"company_linkedin_url": "https://www.linkedin.com/company/ataibeckley",
"event_type": "funding",
"funding_amount": 3800000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion — the biggest deal in psychedelic medicine to date. The deal centers on BPL-003, a 5-MeO-DMT-based drug that showed strong Phase 2 results in treatment-resistant depression.*"
}